Skip to content

AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← Lung cancer: perioperative IO and KRAS NSCLC

EGFR

14 people · 15 posts · 2 abstracts

Heat trend for this story

Heat now 4·Peak in the comparable set 4 (Apr 23 01:00)·Change over 24h in the comparable set –·Participants now 6

Participants counted6
0246
Heat over time
01234Apr22Apr22Apr22Apr23

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

Sherlock-Lung’s 1,209 whole genomes: EGFR more often in never-smokers, KRAS more often in smokers.

Records
Drug / trialReadoutSetting
LCINS / Sherlock-LungEGFRKRAS#LUNGCANCER1,209 WGS: EGFR in never-smokers, KRAS in smokersA separate-disease frame
Other cases in this chapter
Evidence
2968
EGFR S442 mutation confers cetuximab resistance that can be overcome by ERBB2 blockade by trastuzumab-deruxtecan.

Neeraj Joshi, Sarah J. Harmych, Hidenori Tanaka, Galina Bogatcheva, Marisol A. Ramirez, Ramona Graves-Deal, Claiborne W. Tydings, Claudia C. Wahoski, Chelsie K. Sievers, Maria Johnson Irudayam, James N. Higginbotham, Frank L. Revetta, Zhiguo Zhao, Jeffrey L. Franklin, Binyam Yilma, Tina M. O'Grady, Stamatina Fragkogianni, Metamia Ciampricotti, M Kay Washington, Xingyi Guo, Allison S. Walker, Jens Meiler, Qi Liu, Robert J. Coffey, Eben L. Rosenthal, Bhuminder Singh

Read the abstract →
5801
NRX-0305 is an orally bioavailable, pan-mutant BRAF degrader that exhibits single-agent and combination efficacy with MEKi or anti-EGFR across Class 1/2/3 BRAF-mutant cancers

Ya-Wen Lu, Alexandra Borodovsky, Ge Peng, Karthik Arumugam, Paul L. Auger, Delia Bradford, Lilly G. Carlson, Scott K. Kimura, Daniel Medina-Cleghorn, Mariah J. Mesner, Davorka Messmer, Madeleine P. Nemchek, Ryan B. Rountree, Rusha M. Sardhara, Sangita Sridharan, Jennifer M. Stokes, Leslie Tong, Alexandra M. Trotier, Jennifer S. Tung, Ge Wei, Jeffrey Wu, Jordan Ye, Gwenn M. Hansen.

Read the abstract →
Floor
Apr 23Thu
Apr 22Wed
Apr 21Tue
Apr 20Mon
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org